胰激肽原酶针剂联合前列地尔治疗糖尿病肾病的临床观察

Study on therapeutic effect of pancreatic kininogenase combined with alprostadil on diabetic nephropathy

目的观察胰激肽原酶针联合前列地尔治疗早期糖尿病肾病的疗效。方法 68例早期糖尿病肾病患者,随机分为两组,试验组给予胰激肽原酶针联合前列地尔,对照组单独给予前列地尔,疗程14d,观察治疗前后两组血肌酐、尿素氮、尿白蛋白/肌酐比值(ACR)及尿白蛋白排泄率(UAE)的变化。结果试验组治疗后尿白蛋白/肌酐比值及尿白蛋白排泄率较对照组降低更显著(P<0.01);而两组治疗前后血肌酐及血尿素氮水平无统计学差异(P>0.05)。结论胰激肽原酶针联合前列地尔能更明显降低微量尿蛋白水平,是治疗早期糖尿病肾病的更有效治疗方案。

Objective To investigate the therapeutical effects of combined use of pancreatic kininogenase with alprostadil on early diabetic nephropathy. Methods Sixty-eight patients with early diabetic nephropathy were randomly divided into two groups： the treatment group took pancreatic kininogenase and alprostadil,the control group took alprostadil only,for 12 weeks.Urinary albumin/creatinine ratio（ACR）,urinary albumin excretion ratio（UAE）,blood creatinine（Ccr） and urea nitrogen（BUN） were compared between two groups before and after treatment. Results The combination treatment group’s decreased especially in ACR and UAE（P〈0.01）;Ccr and BUN were no significance beweet before treatment and after treatment（P〉0.05）. Conclusions Combined administration of pancreatic kininogenase with alprostadil can significantly decrease the level of microalbuminuria,maybe a more effctively therapeutic option for early diabetic nephropathy.